Human Antibody V
DbTE (Domain based bispecific T cell engager)
VH domain
human GPNMB (DC-HIL, Osteoactivin)
human VCAM-1
therapeutic antibody
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
2
5
2023
pubmed:
18
4
2023
entrez:
17
4
2023
Statut:
ppublish
Résumé
The elevated expression of GPNMB and VCAM-1 has been observed in many cancers including breast cancer, melanoma, and prostate cancers. Such overexpression of GPNMB and VCAM-1 has been associated with poor prognosis and increased cancer metastasis. Thus, GPNMB and VCAM-1 are potential targets for immunotherapies across multiple cancers. In this study, two high-affinity specific human V
Identifiants
pubmed: 37067377
doi: 10.1021/acs.molpharmaceut.3c00173
pmc: PMC10155206
doi:
Substances chimiques
Vascular Cell Adhesion Molecule-1
0
Antibodies
0
Immunoglobulin Variable Region
0
Transcription Factors
0
GPNMB protein, human
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2754-2760Références
Nat Aging. 2021 Dec;1(12):1117-1126
pubmed: 37117524
Cancer Cell. 2011 Oct 18;20(4):538-49
pubmed: 22014578
Am J Transl Res. 2013 Apr 19;5(3):336-46
pubmed: 23634244
NPJ Breast Cancer. 2021 May 20;7(1):57
pubmed: 34016993
Front Immunol. 2021 May 12;12:674739
pubmed: 34054862
J BUON. 2015 Sep-Oct;20(5):1250-7
pubmed: 26537072
Cancer Sci. 2021 May;112(5):1911-1923
pubmed: 33706413
Nat Med. 2019 Jun;25(6):988-1000
pubmed: 31086348
Int J Mol Sci. 2021 Oct 15;22(20):
pubmed: 34681796
Oncotarget. 2016 Mar 22;7(12):13932-44
pubmed: 26883195
Drugs. 2018 Oct;78(15):1639-1642
pubmed: 30298461
APMIS. 2014 Feb;122(2):140-6
pubmed: 23656629
Antib Ther. 2021 Nov 18;4(4):262-272
pubmed: 34909579
Cell Death Dis. 2023 Feb 3;14(2):81
pubmed: 36737605
Oncogene. 2015 Oct;34(43):5494-504
pubmed: 25772243
Cell Signal. 2015 Dec;27(12):2467-73
pubmed: 26386411
Nat Commun. 2015 Apr 30;6:6993
pubmed: 25925867
Front Immunol. 2023 Jan 25;14:1070492
pubmed: 36761762
Cancer Immunol Res. 2016 Oct;4(10):858-868
pubmed: 27549123
Eur J Cancer. 2019 Nov;121:177-183
pubmed: 31586757
Exp Cell Res. 2014 Apr 15;323(1):100-111
pubmed: 24589892
Clin Cancer Res. 2019 Jan 15;25(2):473-477
pubmed: 30254079
Tumour Biol. 2017 Apr;39(4):1010428317699119
pubmed: 28443476
J Invest Dermatol. 2014 Nov;134(11):2784-2794
pubmed: 24936834
Clin Cancer Res. 2010 Apr 1;16(7):2147-56
pubmed: 20215530
J Clin Oncol. 2015 May 10;33(14):1609-19
pubmed: 25847941
Biomolecules. 2021 Jul 31;11(8):
pubmed: 34439797
Cancers (Basel). 2020 Aug 13;12(8):
pubmed: 32823698
Prostate. 2015 Jun;75(8):883-95
pubmed: 25683512
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82
pubmed: 16609006
Front Oncol. 2020 Jul 23;10:1066
pubmed: 32793471
Mol Cancer Res. 2007 Oct;5(10):1001-14
pubmed: 17951401
Clin Cancer Res. 2006 Feb 15;12(4):1373-82
pubmed: 16489096
Sci Transl Med. 2020 Mar 11;12(534):
pubmed: 32161106